{"id":22150,"date":"2026-04-20T07:45:19","date_gmt":"2026-04-20T07:45:19","guid":{"rendered":"https:\/\/www.drfz.de\/?p=22150"},"modified":"2026-04-20T07:45:19","modified_gmt":"2026-04-20T07:45:19","slug":"promising-therapeutic-approach-for-systemic-lupus-erythematosus","status":"publish","type":"post","link":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/","title":{"rendered":"Promising therapeutic approach for systemic lupus erythematosus"},"content":{"rendered":"\n

Phase II study shows clinical improvement with daratumumab<\/strong><\/h2>\n\n\n\n

A team led by PD Dr. Tobias Alexander, head of the Translational Rheumatology<\/em> program area at the DRFZ and of the rheumatology outpatient clinic at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, has shown in a phase-II study that treatment of SLE patients with daratumumab, a drug directed against the CD38 molecule, can significantly reduce disease activity. Among other effects, daratumumab eliminates plasma cells, which are considered key drivers of the disease through production of autoantibodies. The study results were published in the renowned journal Nature Communications<\/em>.<\/strong><\/p>\n\n\n\n

A new phase II study led by PD Dr. Tobias Alexander, head of the Translational Rheumatology program area at the DRFZ and of the rheumatology outpatient clinic at Charit\u00e9, provides promising evidence for a new treatment approach for patients with systemic lupus erythematosus (SLE) who have responded inadequately to previous therapies. In the study, published in Nature Communications, treatment with the anti-CD38 antibody daratumumab led to rapid and sustained clinical improvement as well as a marked reduction in disease-relevant autoantibodies.<\/p>\n\n\n\n

In the phase II trial, ten women with active SLE were treated, all of whom had shown an inadequate response to at least two previous immunosuppressive therapies. In addition to their background medication, the patients received eight weekly subcutaneous injections of daratumumab. Alongside a significant reduction in disease-relevant autoantibodies, the researchers observed rapid and sustained clinical improvement across all organ systems examined. The study also revealed clear immunological changes: treatment with daratumumab led to a depletion of circulating antibody-secreting cells, a reduction in inflammatory type I interferon activity, and profound modulation of T-cell responses. These findings underscore the central role of antibody-producing cells in the development and persistence of SLE.
Daratumumab is an antibody drug against CD38, a molecule that is highly expressed particularly on antibody-secreting cells. The newly published study data build upon the group\u00b4s earlier findings from a small case series, suggesting that targeted CD38 therapy could also have therapeutic potential in autoimmune diseases such as SLE.<\/p>\n\n\n\n


<\/p>\n\n\n\n

\n
\n

Original publication<\/h2>\n \n \n
\n \n
\n
\n \n Ostendorf L, Zernicke J, Klotsche J, Kempkens R, Beenken AE, Biesen R, Cheng Q, Khodadadi L, Guerra GM, Heinrich F, Durek P, Burmester GR, Kr\u00f6nke G, Hiepe F, Mashreghi MF, Alexander T. Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial. Nat Commun. 2026 Feb 3;17(1):1312. doi: 10.1038\/s41467-026-69112-w.<\/a>\n\n \n \n <\/span>\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n\n\n\n\n
\n
\n \n
\n \n\n
\n \"\" <\/div>\n
\n

PD Dr. med. Tobias Alexander<\/h2>\n
\n

\n Leader: Programme Area 4, PA 4 \u2013 Translational Rheumatology <\/p>\n

\n Group leader: Autoimmunology <\/p>\n Liaison working group with Charit\u00e9 – Rheumatology and Clinical Immunology<\/p>\n <\/div>\n <\/div>\n\n

\n

tobias.alexander@charite.de<\/a><\/p>\n <\/div>\n PD Dr. med. Tobias Alexander<\/span><\/a>\n<\/article> <\/div>\n <\/div>\n <\/section>\n","protected":false},"excerpt":{"rendered":"

Phase II study shows clinical improvement with daratumumab A team led by PD Dr. Tobias Alexander, head of the Translational Rheumatology program area at the\u2026<\/p>\n","protected":false},"author":4,"featured_media":22149,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[288,292],"tags":[390,497,480],"programme-area-tax":[181],"working-group-tax":[240],"class_list":["post-22150","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-for-patients","category-news-en","tag-autoimmunology","tag-program-area-4","tag-tobias-alexander","programme-area-tax-programme-area-3","working-group-tax-autoimmunology"],"acf":[],"yoast_head":"\nPromising therapeutic approach for systemic lupus erythematosus - DRFZ<\/title>\n<meta name=\"description\" content=\"Phase II study by Tobias Alexander and team form DRFZ and Charit\u00e9 shows clinical improvement with daratumumab\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Promising therapeutic approach for systemic lupus erythematosus - DRFZ\" \/>\n<meta property=\"og:description\" content=\"Phase II study by Tobias Alexander and team form DRFZ and Charit\u00e9 shows clinical improvement with daratumumab\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/\" \/>\n<meta property=\"og:site_name\" content=\"DRFZ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/drfz.de\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T07:45:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/04\/2026_04_16_-Wirksamkeit-von-Daratumumab_Beitragsbild.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ute Hoffmann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DRFZ_Berlin\" \/>\n<meta name=\"twitter:site\" content=\"@DRFZ_Berlin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ute Hoffmann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/\"},\"author\":{\"name\":\"Ute Hoffmann\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/person\\\/a86dc60d63c6fa52cb3ee62f12c72737\"},\"headline\":\"Promising therapeutic approach for systemic lupus erythematosus\",\"datePublished\":\"2026-04-20T07:45:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/\"},\"wordCount\":339,\"publisher\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2026_04_16_-Wirksamkeit-von-Daratumumab_Beitragsbild.jpg\",\"keywords\":[\"Autoimmunology\",\"Program area 4\",\"Tobias Alexander\"],\"articleSection\":[\"For patients\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/\",\"name\":\"Promising therapeutic approach for systemic lupus erythematosus - DRFZ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2026_04_16_-Wirksamkeit-von-Daratumumab_Beitragsbild.jpg\",\"datePublished\":\"2026-04-20T07:45:19+00:00\",\"description\":\"Phase II study by Tobias Alexander and team form DRFZ and Charit\u00e9 shows clinical improvement with daratumumab\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2026_04_16_-Wirksamkeit-von-Daratumumab_Beitragsbild.jpg\",\"contentUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2026_04_16_-Wirksamkeit-von-Daratumumab_Beitragsbild.jpg\",\"width\":1280,\"height\":720,\"caption\":\"Probenr\u00f6hrchen einer klinischen Studie mit Blut\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/neuigkeiten\\\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Promising therapeutic approach for systemic lupus erythematosus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/\",\"name\":\"DRFZ\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#organization\",\"name\":\"Deutsches Rheuma-Forschungszentrum\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/drfz-footer-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.drfz.de\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/drfz-footer-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Deutsches Rheuma-Forschungszentrum\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/drfz.de\\\/\",\"https:\\\/\\\/x.com\\\/DRFZ_Berlin\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/deutsches-rheuma-forschungszentrum-berlin\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCf8nDuqpkWwcmCWmfSTkE3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.drfz.de\\\/en\\\/#\\\/schema\\\/person\\\/a86dc60d63c6fa52cb3ee62f12c72737\",\"name\":\"Ute Hoffmann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g\",\"caption\":\"Ute Hoffmann\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Promising therapeutic approach for systemic lupus erythematosus - DRFZ","description":"Phase II study by Tobias Alexander and team form DRFZ and Charit\u00e9 shows clinical improvement with daratumumab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/","og_locale":"en_US","og_type":"article","og_title":"Promising therapeutic approach for systemic lupus erythematosus - DRFZ","og_description":"Phase II study by Tobias Alexander and team form DRFZ and Charit\u00e9 shows clinical improvement with daratumumab","og_url":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/","og_site_name":"DRFZ","article_publisher":"https:\/\/www.facebook.com\/drfz.de\/","article_published_time":"2026-04-20T07:45:19+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/04\/2026_04_16_-Wirksamkeit-von-Daratumumab_Beitragsbild.jpg","type":"image\/jpeg"}],"author":"Ute Hoffmann","twitter_card":"summary_large_image","twitter_creator":"@DRFZ_Berlin","twitter_site":"@DRFZ_Berlin","twitter_misc":{"Written by":"Ute Hoffmann","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/#article","isPartOf":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/"},"author":{"name":"Ute Hoffmann","@id":"https:\/\/www.drfz.de\/en\/#\/schema\/person\/a86dc60d63c6fa52cb3ee62f12c72737"},"headline":"Promising therapeutic approach for systemic lupus erythematosus","datePublished":"2026-04-20T07:45:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/"},"wordCount":339,"publisher":{"@id":"https:\/\/www.drfz.de\/en\/#organization"},"image":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/04\/2026_04_16_-Wirksamkeit-von-Daratumumab_Beitragsbild.jpg","keywords":["Autoimmunology","Program area 4","Tobias Alexander"],"articleSection":["For patients","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/","url":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/","name":"Promising therapeutic approach for systemic lupus erythematosus - DRFZ","isPartOf":{"@id":"https:\/\/www.drfz.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/#primaryimage"},"image":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/04\/2026_04_16_-Wirksamkeit-von-Daratumumab_Beitragsbild.jpg","datePublished":"2026-04-20T07:45:19+00:00","description":"Phase II study by Tobias Alexander and team form DRFZ and Charit\u00e9 shows clinical improvement with daratumumab","breadcrumb":{"@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/#primaryimage","url":"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/04\/2026_04_16_-Wirksamkeit-von-Daratumumab_Beitragsbild.jpg","contentUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2026\/04\/2026_04_16_-Wirksamkeit-von-Daratumumab_Beitragsbild.jpg","width":1280,"height":720,"caption":"Probenr\u00f6hrchen einer klinischen Studie mit Blut"},{"@type":"BreadcrumbList","@id":"https:\/\/www.drfz.de\/en\/neuigkeiten\/promising-therapeutic-approach-for-systemic-lupus-erythematosus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.drfz.de\/en\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.drfz.de\/en\/news\/"},{"@type":"ListItem","position":3,"name":"Promising therapeutic approach for systemic lupus erythematosus"}]},{"@type":"WebSite","@id":"https:\/\/www.drfz.de\/en\/#website","url":"https:\/\/www.drfz.de\/en\/","name":"DRFZ","description":"","publisher":{"@id":"https:\/\/www.drfz.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.drfz.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.drfz.de\/en\/#organization","name":"Deutsches Rheuma-Forschungszentrum","url":"https:\/\/www.drfz.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.drfz.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/10\/drfz-footer-logo.svg","contentUrl":"https:\/\/www.drfz.de\/wp-content\/uploads\/2024\/10\/drfz-footer-logo.svg","width":1,"height":1,"caption":"Deutsches Rheuma-Forschungszentrum"},"image":{"@id":"https:\/\/www.drfz.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/drfz.de\/","https:\/\/x.com\/DRFZ_Berlin","https:\/\/www.linkedin.com\/company\/deutsches-rheuma-forschungszentrum-berlin","https:\/\/www.youtube.com\/channel\/UCf8nDuqpkWwcmCWmfSTkE3w"]},{"@type":"Person","@id":"https:\/\/www.drfz.de\/en\/#\/schema\/person\/a86dc60d63c6fa52cb3ee62f12c72737","name":"Ute Hoffmann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/08c654ead40d6cafc50e4ed4fbf2fe4a8a979f96141a813138eec621e1d2879f?s=96&d=mm&r=g","caption":"Ute Hoffmann"}}]}},"_links":{"self":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts\/22150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/comments?post=22150"}],"version-history":[{"count":1,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts\/22150\/revisions"}],"predecessor-version":[{"id":22152,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/posts\/22150\/revisions\/22152"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/media\/22149"}],"wp:attachment":[{"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/media?parent=22150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/categories?post=22150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/tags?post=22150"},{"taxonomy":"programme-area-tax","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/programme-area-tax?post=22150"},{"taxonomy":"working-group-tax","embeddable":true,"href":"https:\/\/www.drfz.de\/en\/wp-json\/wp\/v2\/working-group-tax?post=22150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}